A systematic review of the efficacy of five different formulations of buprenorphine for treating chronic pain begins this issue. This is followed by a paper from Australian authors proposing an interesting new hypothesis for the pathophysiology of CRPS (complex regional pain syndrome), which makes for interesting reading. US research has looked at barriers to providing nonpharmacological therapy for chronic pain, as well as those for reducing opioid use. An RCT has reported that both anxiety and pain can be reduced by the use of melatonin or gabapentin in patients undergoing lumbar surgery. Your input is always valued, so please don't hesitate to send in your feedback and suggestions. Kind Regards, Authors: Aiyer R et al. Summary: This systematic review of 25 RCTs reported on the efficacy of five buprenorphine formulations versus opioid analgesics or placebo for the treatment of chronic pain. Buprenorphine was associated with clinically significant benefits for chronic pain versus comparators in 14 of the studies, including one of six that investigated sublingual and intravenous buprenorphine, two of three that investigated buccal buprenorphine, 10 of 15 that investigated transdermal buprenorphine and the only study that investigated sublingual buprenorphine combined with naloxone. None of the included studies reported any serious adverse events.
Comment: Previous studies have shown physician empathy benefits patients' treatment outcomes. This is a prospective cohort study of 150 pain clinics in Spain showing slight but independent associations between patients' perceptions of physician empathy (Jefferson Scale of Patient Perceptions of Physician Empathy) and changes in pain intensity and health-related QOL, using multiple linear regression models of the changes from baseline to 3 months. We know from previous study that empathy with patients with medically unexplained disorders is thought to reduce stigmatisation. Hence, this suggests that empathy is a component of clinical competence. It will be interesting to see local data. : Pain Med 2018; 19:1304-14 Abstract The impact of perceived injustice on painrelated outcomes: a combined model examining the mediating roles of pain acceptance and anger in a chronic pain sample Authors: Carriere JS et al.
Reference

Summary:
The potential for pain acceptance and anger to mediate the relationship between perceived injustice and adverse pain-related outcomes was explored in this cross-sectional study of 354 tertiary pain centre attendees with chronic pain who completed measures of perceived injustice, pain acceptance, anger, physical function, pain intensity and opioid use. Pain acceptance was found to fully mediate the relationship between perceived injustice and physical function, and also the relationship between perceived injustice and opioid use, and was a partial mediator of the relationship between perceived injustice and pain intensity.
Comment: Perceived injustice is defined as appraisal of severity and irreparability of pain-related losses, a sense of unfairness and blame. It has been shown to be a significant barrier to effective recovery. This is a cross-sectional study of chronic pain patients in a tertiary pain centre (n=354) showing that pain acceptance (CPAQ-8), but not anger (PROMIS anger), mediated the relationship between perceived injustice (IEQ) and physical function, and also between perceived injustice and opioid use, using multiple mediation analysis. It is between perceived injustice and opioid use, using multiple mediation analysis. It is possible that individuals with low pain acceptance are more likely to maintain disability behaviours to seek adequate retribution for losses, and use opioids for not only pain, but also distress. However, a previous study by Scott et al. showed that the state anger subscale of STAI mediated the relationship between perceived injustice and pain intensity. This study implied that it is important to integrate interventions to improve pain acceptance in the treatment programme. Before prescribing, please review the Product Information available at www.seqirus.com.au/PI PBS Information: Restricted benefit. Chronic severe disabling pain not responding to non-narcotic analgesics. Authority required for increased maximum quantities and/or repeats. Refer to PBS schedule for full restricted benefit and authority information.
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Independent commentary by Dr Tim Ho, who is a rehabilitation and pain specialist at Inner West Pain Centre. Tim also works in work capacity centre and addiction medicine. His interests are chronic musculoskeletal pain, neuropathic pain, visceral pain and headache. His research interests are management of comorbid chronic pain and addiction, return-to-work programmes, osseointegration and nursing home resident pain management.
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Comparison of effects of melatonin and gabapentin on post operative anxiety and pain in lumbar spine surgery Authors: Javaherforooshzadeh F et al. Summary: Patients undergoing lumbar surgery with fixed method general anaesthesia were randomised to receive melatonin 6mg (n=30), gabapentin 600mg (n=30) or placebo (n=30), administered 100 minutes before surgery. Assessments of pain, satisfaction and anxiety were undertaken at 1, 2, 6, 12 and 24 hours postsurgery, with anxiety also assessed 15 minutes before surgery. Compared with placebo, melatonin and gabapentin were both associated with significant differences in mean VAS scores (p=0.02) and a significant reduction in the intensity of anxiety (p=0.01).
Comment: Previous study has suggested an anxiolytic effect of preoperative melatonin, without mental dysfunction. There have been conflicting reports on its analgesic properties in the acute postoperative setting. This is a double-blinded, controlled, clinical study (n=90) showing preoperative melatonin or gabapentin is associated with reductions in anxiety (VAS) and pain (VAS) in lumbar surgery, at 12 hours and 24 hours. Melatonin 6mg, gabapentin 600mg or placebo was given 100 minutes before induction. Melatonin is thought to activate opioid receptors (hyperpolarisation due to potassium influx) and decrease cAMP formation in neurons. Furthermore, melatonin can reduce inflammation by reducing expression of lipoxygenase and cyclo-oxgenase. Further validation studies with larger sample sizes are warranted.
Reference: Anesthesiol Pain Med 2018;8:e68763 Abstract
Comparison of anterior suprascapular, supraclavicular, and interscalene nerve block approaches for major outpatient arthroscopic shoulder surgery Authors: Auyong DB et al. Summary: Patients scheduled for arthroscopic shoulder surgery (n=189) were randomised to interscalene, supraclavicular or anterior suprascapular block using 15mL of 0.5% ropivacaine in this trial, with a 1-point margin on an 11-point numerical rating pain scale set to define noninferiority. The mean postsurgery pain scores in the respective interscalene, supraclavicular and anterior suprascapular groups were 1.9, 2.3 and 2.0, with differences of 0.4 between the supraclavicular and interscalene groups (p=0.088 for noninferiority) and 0.1 between the suprascapular and interscalene groups (p=0.012 for noninferiority). Opioid consumption was similar among groups, while preservation of vital capacity was better in the anterior suprascapular and supraclavicular groups compared with the interscalene group.
Comment: Interscalene block may be associated with phrenic nerve block, and symptomatic hemidiaphragmatic paralysis after shoulder surgery is challenging to treat. Siegenthaler et al. have described selective anterior suprascapular block within the supraclavicular fossa to avoid phrenic nerve paresis. This is a randomised, controlled, double-blind trial showing that anterior suprascapular block, but not supraclavicular block, is noninferior to interscalene block for analgesia (VAS), and is superior in preserving pulmonary function (vital capacity) for major arthroscopic shoulder surgery. Patients with pre-existing lung dysfunction were excluded, but the data support anterior suprascapular block rather than interscalene block to lessen pulmonary side effects. : Anesthesiology 2018; 129:47-57 Abstract Transcranial alternating current stimulation at alpha frequency reduces pain when the intensity of pain is uncertain Authors: Arendsen LJ et al.
Reference
Summary: This research explored the ability of somatosensory transcranial ACS (alternating current stimulation) at the alpha frequency (which allows the potential causal relationship between alpha activity and pain to be examined) to reduce pain experiences, and if this is influenced by uncertainty about pain intensity. Twenty-three participants were each subjected to both α-transcranial ACS and sham stimulation, during which their perceived pain intensity and unpleasantness were assessed; visual cues preceding pain stimuli were used to manipulate uncertainty. Significant transcranial ACS by uncertainty by stimulus intensity interactions were detected for both reported pain intensity and unpleasantness. Ultrasound-guided percutaneous peripheral nerve stimulation: neuromodulation of the sciatic nerve for postoperative analgesia following ambulatory foot surgery Authors: Ilfeld BM Summary: This proof-of-concept study set out to evaluate the feasibility of using percutaneous sciatic nerve stimulation to treat immediate postoperative pain in patients who had undergone ambulatory foot surgery. The participants received 5 minutes of real and sham stimulation in a randomised crossover design, followed by continuous stimulation until lead removal on postoperative days 14-28. A downward trajectory in pain was seen during the 5 minutes of active stimulation in the four participants who received this first, while the three who received the sham intervention initially experienced no change until their subsequent 5-minute stimulation crossover. All seven participants experienced a decrease in pain scores to 57% of baseline during the subsequent 30 minutes of stimulation. A continuous popliteal nerve block was provided for rescue analgesia for three participants during postoperative days 0-3. Resting and dynamic numerical rating scale pain scores averaged <1 and opioid use averaged <1 tablet per day with active stimulation. There was one lead dislodgement, two lead fractures during use and one lead fracture during intentional withdrawal.
Comment: This is a proof-of-concept study, using a randomised, doublemasked controlled design (n=7) of percutaneous electrical lead insertion posterior to the sciatic nerve with ultrasound, showing reduced pain and decrease opioid requirement after ambulatory hallux valgus surgery. No sensory deficits or motor block was detected. Stimulation was delivered at 100Hz, at sensory or motor threshold, with amplitude range of 0.2-2mA and pulse duration of 15-200 msec. Lead insertion was between sciatic bifurcation and subgluteal region. The author noted previous experience with increased fracture of the popliteal lead, suggesting increased lead tension. I look forward to the next instalment of the study.
